{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:06:07Z","timestamp":1791356767392,"version":"4.3.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spain as multiple other countries has been experiencing an increasing and sustained trend in the use of psychotropic medications since the mid 90s. Recent studies show public health measures implemented to control SARS-Cov2, such as mobility restrictions and the shutdown of nonessential activities increased mental suffering, even contributing to a higher number of anxiety, depression and insomnia disorders that could lead to an increase in the consumption of psychotropics.<\/jats:p>\n                    <jats:p>The aims were: 1) Evaluate the temporal trend in psychotropic consumption by pharmacological subgroup, sex, and age group 2) Estimate the effect of the COVID-19 pandemic in the use of psychotropic drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study, retrieving all prescriptions of anxiolytics, hypnotics and sedatives, and antidepressants dispensed in pharmacies of Asturias (Northern Spain) for Primary Care patients for the period 2018\u20132021.<\/jats:p>\n                    <jats:p>\n                      We presented the data expressed in Daily Defined Doses (DDDs) for 1000 persons\/day (DHD). To estimate changes in DHDs by year and age group we conducted two multiple linear regressions (one for males and one for females) for every pharmacological subgroup studied. Changes were considered statistically significant when the regression coefficient was\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05. We used the Software R 4.1.0.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For the studied period, the highest DHDs are for antidepressants, although all of the subgroups experienced an increase in consumption rates.<\/jats:p>\n                    <jats:p>Women consumed more psychotropic drugs than men. In 2021, 372 out of every 1000 women were taking daily 1 DDD of these drugs versus 184 out of every 1000 men.<\/jats:p>\n                    <jats:p>Consumption rates for all psychotropic drugs progressively increases with age. Conversely, the biggest increases in consumption were among the youngest age groups (0\u201314 and 15\u201329\u2009years) for women, while for men there is more variability.<\/jats:p>\n                    <jats:p>The regression models suggest an upward trend in psychotropic consumption during all the period, especially remarkable from 2020, for both genders and all age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>- The consumption of psychotropic drugs has gradually increased over the last 4 years, with a significant boost starting in 2020 for both sexes, matching the start of the SARS-COV2 pandemic and the implementation of strict Public Health measures to contain it.<\/jats:p>\n                    <jats:p>- The increase observed on children and adolescents is a matter of concern.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-023-15360-0","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:33:00Z","timestamp":1679848380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Psychotropic consumption before and during COVID-19 in Asturias, Spain"],"prefix":"10.1186","volume":"23","author":[{"given":"Mar\u00eda Luisa Nicieza","family":"Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Fern\u00e1ndez","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Fern\u00e1ndez","family":"Bret\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta M.","family":"Mart\u00ednez Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio Su\u00e1rez","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"15360_CR1","doi-asserted-by":"crossref","unstructured":"Garc\u00eda del Pozo J, de Abajo Iglesias FJ, Carvajal Garc\u00eda-Pando A, Montero Corominas D, Madurga Sanz M, Garc\u00eda del Pozo V. The use of anxiolytic and hypnotic drugs in Spain (1995-2002). Rev Esp Salud Publica. 2004;78(3). Available from: https:\/\/scielo.isciii.es\/pdf\/resp\/v78n3\/original4.pdf.","DOI":"10.1590\/S1135-57272004000300007"},{"key":"15360_CR2","unstructured":"Spanish Agency of Medicines and Medical Devices (AEMPS). Use of antidepressant drugs in Spain during the 2000-2013 period. [Internet]. 2015. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/observatorio\/docs\/antidepresivos-2000-2013.pdf."},{"key":"15360_CR3","unstructured":"Spanish Agency of Medicines and Medical Devices (AEMPS). Use of anxiolytic and hypnotic drugs in Spain during the period 2000-2012. [Internet]. 2014. Available from https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/observatorio\/docs\/ansioliticos_hipnoticos-2000-2012.pdf."},{"key":"15360_CR4","unstructured":"United Nations. Report of the international narcotics control board for 2019. [Internet]. 2020. Available from: https:\/\/www.incb.org\/documents\/Publications\/AnnualReports\/AR2019\/Annual_Report\/Spanish_ebook_AR2019.pdf."},{"key":"15360_CR5","unstructured":"Spanish Observatory on Drugs and Addictions. Informe 2021: Alcohol, tabaco y drogas ilegales en Espa\u00f1a. [Internet]. 2021. Available from: https:\/\/pnsd.sanidad.gob.es\/profesionales\/sistemasInformacion\/informesEstadisticas\/pdf\/2021OEDA-INFORME.pdf."},{"key":"15360_CR6","unstructured":"United Nations. Psychotropic substances 2021: assessments of annual medical and scientific requirements for 2022. [Internet]. 2022. Available from: https:\/\/www.incb.org\/documents\/Psychotropics\/technical-publications\/2021\/21-08898_Psychotropics_2021_ebook.pdf."},{"key":"15360_CR7","unstructured":"Spanish Agency of Medicines and Medical Devices (AEMPS). Use of anxiolytics and hypnotics drugs in Spain [Internet]. 2022. Available from: https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/observatorio-de-usode-medicamentos\/informes-ansioliticos-hipnoticos\/."},{"key":"15360_CR8","unstructured":"Base Datos Cl\u00ednicos de Atenci\u00f3n Primaria (BDCAP). Salud mental en datos: prevalencia de los problemas de salud y consumo de psicof\u00e1rmacos y f\u00e1rmacos relacionados a partir de registros cl\u00ednicos de atenci\u00f3n primaria. [Internet]. 2021. Available from: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/estadisticas\/estMinisterio\/SIAP\/Salud_mental_datos.pdf."},{"issue":"4","key":"15360_CR9","first-page":"650","volume":"15","author":"R Secades Villa","year":"2003","unstructured":"Secades Villa R, Rodr\u00edguez Garc\u00eda E, Valderrey Barbero J, Fern\u00e1ndez Hermida JR, Vallejo Seco G, Jim\u00e9nez Garc\u00eda JM. El consumo de psicof\u00e1rmacos en pacientes que acuden a Atenci\u00f3n Primaria en el Principado de Asturias (Espa\u00f1a). Psichothema. 2003;15(4):650\u20135.","journal-title":"Psichothema."},{"issue":"2","key":"15360_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.gaceta.2019.03.002","volume":"34","author":"J Henares Montiel","year":"2020","unstructured":"Henares Montiel J, Ruiz-P\u00e9rez I, Sordo L. Mental health in Spain and differences by sex, and by autonomous communities. Gac Sanit. 2020;34(2):114\u20139.","journal-title":"Gac Sanit"},{"issue":"9","key":"15360_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.medcli.2020.07.009","volume":"155","author":"A Gonz\u00e1lez-Rodr\u00edguez","year":"2020","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Labad J. Mental health in times of COVID: thoughts after the state of alarm. Med Clin (Barc). 2020;155(9):392\u20134.","journal-title":"Med Clin (Barc)"},{"issue":"7","key":"15360_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.aprim.2021.102143","volume":"53","author":"F Buitrago Ram\u00edrez","year":"2021","unstructured":"Buitrago Ram\u00edrez F, Ciurana Misol R, Fern\u00e1ndez Alonso MC, Tiz\u00f3n Garc\u00eda JL. Impact of the COVID-19 pandemic on the mental health of the general population: reflections and proposals. Aten Primaria. 2021;53(7):102143.","journal-title":"Aten Primaria"},{"issue":"10","key":"15360_CR13","doi-asserted-by":"publisher","DOI":"10.2196\/28071","volume":"10","author":"A Aguiar","year":"2021","unstructured":"Aguiar A, Pinto M, Duarte R. Psychological impact of the COVID-19 pandemic and social determinants on the Portuguese population: protocol for a web-based cross-sectional study. JMIR Res Protoc. 2021;10(10):e28071.","journal-title":"JMIR Res Protoc"},{"key":"15360_CR14","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","unstructured":"COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 Due to the COVID-19 pandemic. Lancet. 2021;398:1700\u201312.","journal-title":"Lancet."},{"issue":"11","key":"15360_CR15","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamapediatrics.2021.2482","volume":"175","author":"N Racine","year":"2021","unstructured":"Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S. Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a Meta-analysis. JAMA Pediatr. 2021;175(11):1142\u201350.","journal-title":"JAMA Pediatr"},{"issue":"11","key":"15360_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamapediatrics.2021.2479","volume":"175","author":"TD Benton","year":"2021","unstructured":"Benton TD, Boyd RC, Njoroge WFM. Addressing the global crisis of child and adolescent mental health. JAMA Pediatr. 2021;175(11):1108\u201310.","journal-title":"JAMA Pediatr"},{"issue":"7","key":"15360_CR17","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.3390\/ijerph18073432","volume":"18","author":"S Meherali","year":"2021","unstructured":"Meherali S, Punjani N, Louie-Poon S, Abdul Rahim K, Das JK, Salam RA, et al. Mental health of children and adolescents amidst COVID-19 and past pandemics: a rapid systematic review. Int J Environ Res Public Health. 2021;18(7):3432.","journal-title":"Int J Environ Res Public Health"},{"key":"15360_CR18","first-page":"10","volume":"18","author":"Q Guti\u00e9rrez","year":"2022","unstructured":"Guti\u00e9rrez Q, del \u00c1lamo J. Impacto de la pandemia COVID-19 en la salud mental de ni\u00f1os y adolescents. Evid Pediatr. 2022;18:10.","journal-title":"Evid Pediatr"},{"key":"15360_CR19","unstructured":"National Institute of statistics, Spain (INE). Suicide mortality rate by autonomous community, age, sex, and period. [Internet]. 2022. Available from: https:\/\/www.ine.es\/jaxi\/Datos.htm?tpx=46688#!tabs-mapa."},{"issue":"5","key":"15360_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1176\/appi.ps.202000393","volume":"72","author":"F Bernardini","year":"2021","unstructured":"Bernardini F, Attademo L, Rotter M, Compton MT. Social determinants of mental health as mediators and moderators of the mental health impacts of the COVID-19 pandemic. Psychiatr Serv Wash DC. 2021;72(5):598\u2013601.","journal-title":"Psychiatr Serv Wash DC"},{"key":"15360_CR21","unstructured":"Sociedad Asturiana de Estudios Econ\u00f3micos e Industriales (SADEI). Poblaci\u00f3n seg\u00fan sexo y edad. [Internet]. 2022. Available from: https:\/\/www.sadei.es\/sadei\/poblacion\/padrones-de-habitantes_167_1_ap.html?f=02__04__02$$02040202.px."},{"key":"15360_CR22","first-page":"151","volume":"28","author":"HP Ruiz-Valdepe\u00f1as","year":"1992","unstructured":"Ruiz-Valdepe\u00f1as HP. Reconversi\u00f3n y reestructuraci\u00f3n industrial en Asturias. Er\u00eda Rev Cuatrimest Geogr. 1992;28:151\u201364.","journal-title":"Er\u00eda Rev Cuatrimest Geogr"},{"key":"15360_CR23","unstructured":"National Institute of Statistics, Spain (INE). Indicadores de Estructura de la Poblaci\u00f3n. Proporci\u00f3n de personas mayores de cierta edad por provincia. [Internet]. 2022. Available from: https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=1488."},{"key":"15360_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.17811\/er.99.2016.95-108","volume":"99","author":"B L\u00f3pez Fern\u00e1ndez","year":"2016","unstructured":"L\u00f3pez Fern\u00e1ndez B. Poblamiento y declive demogr\u00e1fico en Asturias, 2000 2014. Er\u00eda. 2016;99:95\u2013108.","journal-title":"Er\u00eda."},{"key":"15360_CR25","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs: Structure and principles [Internet]. 2022. Available from: https:\/\/www.whocc.no\/atc\/structure_and_principles\/."},{"key":"15360_CR26","unstructured":"R Core Team. R: a language and environment for statistical computing [internet]. Vienna; 2016. Available from: https:\/\/www.R-project.org\/"},{"key":"15360_CR27","unstructured":"Spain. Royal Decree 463\/2020 of March 14, 2020, declaring a state of alarm for the management of the health crisis situation caused by COVID-19. [Internet]. 2020. Available from: https:\/\/www.boe.es\/buscar\/act.php?id=BOE-A-2020-3692."},{"key":"15360_CR28","doi-asserted-by":"publisher","first-page":"19336","DOI":"10.1038\/s41598-022-22085-4","volume":"12","author":"F Marazzi","year":"2022","unstructured":"Marazzi F, Piano Mortari A, Belotti F, Carr\u00e0 G, Cattuto C, Kopinska J, et al. Psychotropic drug purchases during the COVID-19 pandemic in Italy and their relationship with mobility restrictions. Sci Rep. 2022;12:19336.","journal-title":"Sci Rep"},{"issue":"11","key":"15360_CR29","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.3390\/ijerph18115944","volume":"18","author":"M S\u00e1nchez D\u00edaz","year":"2021","unstructured":"S\u00e1nchez D\u00edaz M, Mart\u00edn-Calvo ML, Mateos-Campos R. Trends in the use of anxiolytics in castile and Leon, Spain, between 2015-2020: evaluating the impact of COVID-19. Int J Environ Res Public Health. 2021;18(11):5944.","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"15360_CR30","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.3390\/ijerph19084782","volume":"19","author":"MDC Gonz\u00e1lez-L\u00f3pez","year":"2022","unstructured":"Gonz\u00e1lez-L\u00f3pez MDC, D\u00edaz-Calvo V, Ru\u00edz-Gonz\u00e1lez C, Nievas-Soriano BJ, Rebollo-Lavado B, Parr\u00f3n-Carre\u00f1o T. Consumption of psychiatric drugs in primary care during the COVID-19 pandemic. Int J Environ Res Public Health. 2022;19(8):4782.","journal-title":"Int J Environ Res Public Health"},{"key":"15360_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2022.154656","volume":"829","author":"N Diaz-Camal","year":"2022","unstructured":"Diaz-Camal N, Cardoso-Vera JD, Islas-Flores H, G\u00f3mez-Oliv\u00e1n LM, Mej\u00eda-Garc\u00eda A. Consumption and ocurrence of antidepressants (SSRIs) in pre- and post-COVID-19 pandemic, their environmental impact and innovative removal methods: a review. Sci Total Environ. 2022;829:154656.","journal-title":"Sci Total Environ"},{"key":"15360_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.886652","volume":"13","author":"C Leong","year":"2022","unstructured":"Leong C, Kowalec K, Eltonsy S, Bolton JM, Enns MW, Tan Q, et al. Psychotropic medication use before and during COVID-19: a population-wide study. Front Pharmacol. 2022;13:886652.","journal-title":"Front Pharmacol"},{"issue":"4","key":"15360_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/jech-2021-216732","volume":"76","author":"M Estrela","year":"2022","unstructured":"Estrela M, Silva TM, Gomes ER, Pi\u00f1eiro M, Figueiras A, Roque F, et al. Prescription of anxiolytics, sedatives, hypnotics and antidepressants in outpatient, universal care during the COVID-19 pandemic in Portugal: a nationwide, interrupted time-series approach. J Epidemiol Community Health. 2022;76(4):335\u201340.","journal-title":"J Epidemiol Community Health"},{"issue":"10","key":"15360_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.31012","volume":"4","author":"SA Milani","year":"2021","unstructured":"Milani SA, Raji MA, Chen L, Kuo YF. Trends in the use of benzodiazepines, Z-hypnotics, and serotonergic drugs among US women and men before and during the COVID-19 pandemic. JAMA Netw Open. 2021;4(10):e2131012.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"15360_CR35","first-page":"100","volume":"17","author":"S Llorente Alvarez","year":"1996","unstructured":"Llorente Alvarez S, L\u00f3pez Ruiz T, Garc\u00eda Lavandera LJ, Alonso Fern\u00e1ndez M, Alonso Arias P, Mu\u00f1oz BP. Profile of the over-user of a health center. Aten Primaria. 1996;17(2):100\u20136.","journal-title":"Aten Primaria"},{"issue":"4","key":"15360_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.semerg.2015.05.011","volume":"42","author":"N Parejo Maestre","year":"2016","unstructured":"Parejo Maestre N, Lend\u00ednez-de la Cruz JM, Berm\u00fadez-Torres FM, G\u00f3nzalez-Contero L, de Los G-E, Monteros MP, et al. Prevalence and factors associated with frequent attendence in family medicine clinic. Semergen. 2016;42(4):216\u201324.","journal-title":"Semergen."},{"issue":"1","key":"15360_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20344\/amp.4007","volume":"26","author":"J Gomes","year":"2013","unstructured":"Gomes J, Machado A, Cavadas LF, Teixeira H, Pires P, Santos JA, et al. The primary care frequent attender profile. Acta Medica Port. 2013;26(1):17\u201323.","journal-title":"Acta Medica Port"},{"key":"15360_CR38","unstructured":"Ministry of Health and consumers\u2019 affairs (Spain). Health and gender report 2006. The central ages of life. [Internet]. 2008. Available from: https:\/\/www.sanidad.gob.es\/ciudadanos\/proteccionSalud\/mujeres\/docs\/healthAndGender2006Report.pdf."},{"key":"15360_CR39","unstructured":"Mill\u00e1n Carrasco A, P\u00e9rez Corral O, Maroto Navarro G, Garc\u00eda Calvente MM. Women's mental health. Myths and realities Notebooks for women's health [Internet] 2021. Available from: https:\/\/consaludmental.org\/centro-documentacion\/salud-mental-mujeres-mitos-realidades\/."},{"issue":"4","key":"15360_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/acps.13483","volume":"146","author":"I Kuitunen","year":"2022","unstructured":"Kuitunen I. Psychotropic medication use in pediatric population during COVID\u201019 pandemic. Acta Psychiatr Scand. 2022;146(4):381\u20133.","journal-title":"Acta Psychiatr Scand"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15360-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-15360-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15360-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:33:12Z","timestamp":1679848392000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-15360-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["15360"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-15360-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1859526\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"14 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We requested the approval of the study to the Ethics Committee for Research with Medicines of the Principality of Asturias (CEImPA), attached to the Regional Ministry of Health, whose purpose is to evaluate all the research studies carried out on human beings in any of the health centers, services and establishments in the Autonomous Community of the Principality of Asturias. The Research Ethics Committee is the Committee of reference for any research study on human beings that is carried out, regardless of the methodology and the promoter of the study.The application for authorization of the study was submitted online at the following address:\n                      \n                      One of the forms required by this Committee for the approval of observational studies, as in our case, is the authorization of the head of the department where the study is performed. In our case, since it is a study that includes consumption data from the entire region, we requested authorization from the Director General of Health Policy and Planning. This permission was sent to the CEImPA as part of the formal ethical approval required by that Committee (attached).Another form required by CEImPA for study approval is the Principal Investigator Commitment. In our case, the principal investigator commits to conduct the study anonymously, without access to the patients\u2019 medical records, in compliance with the Organic Law on Data Protection 03\/2018 of December 5. This commitment was sent to the CEImPA as part of the formal ethical approval required by that Committee (attached).We have also requested an informed consent exemption from the CEImPA, considering that this is a study of drug use, for which no personal data of the participants (name, surname, address, medical history number, etc.) or diagnoses or clinical and\/or analytical variables are required, so that no permission is needed for access to the computerized clinical history of the patients, nor was it necessary to obtain an identification code of the patients. The data refer to the Defined Daily Doses per 1000 inhabitants consumed in each study year and to the number of containers dispensed for the 3 pharmacological subgroups (anxiolytics, hypnotics and sedatives and antidepressants). The data are presented aggregated by sex and age groups in the form of consumption tables. The study is anonymized, in compliance with the data protection law (Organic Law 3\/2018, of December 5, on Personal Data Protection and Guarantee of Digital Rights) and was conducted in accordance with the relevant guidelines and regulations.The Ethics Committee for Research with Medicines of the Principality of Asturias (CEImPA) has waived the need for informed consent for this study.The approval of the study is given by the Ethics Committee for Research with Medicines of the Principality of Asturias (CEImPA). The approval is attached.This study was carried out in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"494"}}